{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:50:46Z","timestamp":1780530646520,"version":"3.54.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180888"],"award-info":[{"award-number":["CA180888"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180819"],"award-info":[{"award-number":["CA180819"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180820"],"award-info":[{"award-number":["CA180820"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180821"],"award-info":[{"award-number":["CA180821"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180868"],"award-info":[{"award-number":["CA180868"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180863"],"award-info":[{"award-number":["CA180863"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189952"],"award-info":[{"award-number":["CA189952"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189953"],"award-info":[{"award-number":["CA189953"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180834"],"award-info":[{"award-number":["CA180834"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189858"],"award-info":[{"award-number":["CA189858"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA190002"],"award-info":[{"award-number":["CA190002"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189808"],"award-info":[{"award-number":["CA189808"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180801"],"award-info":[{"award-number":["CA180801"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189821"],"award-info":[{"award-number":["CA189821"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180846"],"award-info":[{"award-number":["CA180846"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189856"],"award-info":[{"award-number":["CA189856"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180830"],"award-info":[{"award-number":["CA180830"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189972"],"award-info":[{"award-number":["CA189972"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180835"],"award-info":[{"award-number":["CA180835"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180858"],"award-info":[{"award-number":["CA180858"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189817"],"award-info":[{"award-number":["CA189817"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180818"],"award-info":[{"award-number":["CA180818"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189872"],"award-info":[{"award-number":["CA189872"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189804"],"award-info":[{"award-number":["CA189804"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189853"],"award-info":[{"award-number":["CA189853"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189860"],"award-info":[{"award-number":["CA189860"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189954"],"award-info":[{"award-number":["CA189954"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189830"],"award-info":[{"award-number":["CA189830"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189822"],"award-info":[{"award-number":["CA189822"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189971"],"award-info":[{"award-number":["CA189971"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA180828"],"award-info":[{"award-number":["CA180828"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189957"],"award-info":[{"award-number":["CA189957"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189997"],"award-info":[{"award-number":["CA189997"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189854"],"award-info":[{"award-number":["CA189854"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189809"],"award-info":[{"award-number":["CA189809"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189829"],"award-info":[{"award-number":["CA189829"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA189873"],"award-info":[{"award-number":["CA189873"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA13612"],"award-info":[{"award-number":["CA13612"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA46282"],"award-info":[{"award-number":["CA46282"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA45450"],"award-info":[{"award-number":["CA45450"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA11083"],"award-info":[{"award-number":["CA11083"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA35119"],"award-info":[{"award-number":["CA35119"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA35128"],"award-info":[{"award-number":["CA35128"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA46368"],"award-info":[{"award-number":["CA46368"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA52654"],"award-info":[{"award-number":["CA52654"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA74647"],"award-info":[{"award-number":["CA74647"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA63850"],"award-info":[{"award-number":["CA63850"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA12644"],"award-info":[{"award-number":["CA12644"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA46113"],"award-info":[{"award-number":["CA46113"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA04919"],"award-info":[{"award-number":["CA04919"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA73590"],"award-info":[{"award-number":["CA73590"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA22433"],"award-info":[{"award-number":["CA22433"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA68183"],"award-info":[{"award-number":["CA68183"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA58723"],"award-info":[{"award-number":["CA58723"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA37981"],"award-info":[{"award-number":["CA37981"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA76447"],"award-info":[{"award-number":["CA76447"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA58416"],"award-info":[{"award-number":["CA58416"]}]},{"name":"National Cancer Institute of the National Institutes of Health","award":["CA76448"],"award-info":[{"award-number":["CA76448"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Berlex Pharmaceuticals"},{"name":"Bayer HealthCare Pharmaceuticals Inc"},{"name":"Roche\/Genentech"},{"name":"Novartis Pharmaceuticals, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Adjuvant bisphosphonates, when given in a low-estrogen environment, can decrease breast cancer recurrence and death. Treatment guidelines include recommendations for adjuvant bisphosphonates in postmenopausal patients. SWOG\/Alliance\/Canadian Cancer Trials Group\/ECOG-ACRIN\/NRG Oncology study S0307 compared the efficacy of three bisphosphonates in early-stage breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients with stage I\u2013III breast cancer were randomly assigned to 3\u2009years of intravenous zoledronic acid, oral clodronate, or oral ibandronate. The primary endpoint was disease-free survival (DFS) with overall survival as a secondary outcome. All statistical tests were two-sided.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 6097 patients enrolled. Median age was 52.7\u2009years. Prior to being randomly assigned, 73.2% patients indicated preference for oral vs intravenous formulation. DFS did not differ across arms in a log-rank test (P\u2009=\u2009.49); 5-year DFS was 88.3% (zoledronic acid: 95% confidence interval [CI] = 86.9% to 89.6%), 87.6% (clodronate: 95% CI = 86.1% to 88.9%), and 87.4% (ibandronate: 95% CI = 85.6% to 88.9%). Additionally, 5-year overall survival did not differ between arms (log rank P\u2009=\u2009.50) and was 92.6% (zoledronic acid: 95% CI = 91.4% to 93.6%), 92.4% (clodronate: 95% CI = 91.2% to 93.5%), and 92.9% (ibandronate: 95% CI = 91.5% to 94.1%). Bone as first site of recurrence did not differ between arms (P\u2009=\u2009.93). Analyses based on age and tumor subtypes showed no treatment differences. Grade 3\/4 toxicity was 8.8% (zoledronic acid), 8.3% (clodronate), and 10.5% (ibandronate). Osteonecrosis of the jaw was highest for zoledronic acid (1.26%) compared with clodronate (0.36%) and ibandronate (0.77%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We found no evidence of differences in efficacy by type of bisphosphonate, either in overall analysis or subgroups. Despite an increased rate of osteonecrosis of the jaw with zoledronic acid, overall toxicity grade differed little across arms. Given that patients expressed preference for oral formulation, efforts to make oral agents available in the United States should be considered.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djz215","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T20:08:41Z","timestamp":1572293321000},"page":"698-707","source":"Crossref","is-referenced-by-count":70,"title":["Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307"],"prefix":"10.1093","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-9928","authenticated-orcid":false,"given":"Julie R","family":"Gralow","sequence":"first","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4651-2282","authenticated-orcid":false,"given":"William E","family":"Barlow","sequence":"first","affiliation":[{"name":"SWOG Statistical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H G","family":"Paterson","sequence":"first","affiliation":[{"name":"Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling L","family":"M'iao","sequence":"first","affiliation":[{"name":"SWOG Statistical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danika L","family":"Lew","sequence":"first","affiliation":[{"name":"SWOG Statistical Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison T","family":"Stopeck","sequence":"first","affiliation":[{"name":"Stony Brook Cancer Center, Stony Brook University Cancer Center, Stony Brook, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-7575","authenticated-orcid":false,"given":"Daniel F","family":"Hayes","sequence":"first","affiliation":[{"name":"University of Michigan, Ann Arbor, MI (DFH, CHVP); Columbia University, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8807-153X","authenticated-orcid":false,"given":"Dawn L","family":"Hershman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M","family":"Schubert","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0738-2713","authenticated-orcid":false,"given":"Mark","family":"Clemons","sequence":"first","affiliation":[{"name":"Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H","family":"Van Poznak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C","family":"Dees","sequence":"first","affiliation":[{"name":"University of North Carolina, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1257-7731","authenticated-orcid":false,"given":"James N","family":"Ingle","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla I","family":"Falkson","sequence":"first","affiliation":[{"name":"University of Alabama, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D","family":"Elias","sequence":"first","affiliation":[{"name":"University of Colorado, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Messino","sequence":"first","affiliation":[{"name":"Cancer Care of WNC, Greenville, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H","family":"Margolis","sequence":"first","affiliation":[{"name":"Beaumont NCORP\/William Beaumont Hospital, Royal Oak, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker R","family":"Dakhil","sequence":"first","affiliation":[{"name":"Wichita NCORP, Wichita, KS"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen K","family":"Chew","sequence":"first","affiliation":[{"name":"University of California at Davis, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Z","family":"Dammann","sequence":"first","affiliation":[{"name":"University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S","family":"Abrams","sequence":"first","affiliation":[{"name":"Cancer Therapy and Evaluation Program, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B","family":"Livingston","sequence":"first","affiliation":[{"name":"University of Arizona, Tucson, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4873-4412","authenticated-orcid":false,"given":"Gabriel N","family":"Hortobagyi","sequence":"first","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"2020071308425005000_djz215-B1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.critrevonc.2017.04.008","article-title":"Systematic review and meta-analysis on the proportion of patients with breast cancer who develop bone metastases","volume":"115","author":"Body","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2020071308425005000_djz215-B2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.clbc.2012.11.001","article-title":"Incidence and patterns of distant metastases for patients with early-stage breast cancer after breast conservation treatment","volume":"13","author":"Berman","year":"2013","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"2020071308425005000_djz215-B3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2020071308425005000_djz215-B4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ctrv.2012.02.007","article-title":"Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine\/paracrine microenvironment and implications for treatment with bisphosphonates","volume":"38","author":"Wilson","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"16","key":"2020071308425005000_djz215-B5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"key":"2020071308425005000_djz215-B6","first-page":"S9","article-title":"Bone resorption and turnover in health and disease","volume":"8","author":"Mundy","year":"1987","journal-title":"Bone"},{"issue":"12","key":"2020071308425005000_djz215-B7","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","article-title":"Management of aromatase inhibitor\u2013associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment","volume":"22","author":"Hadji","year":"2011","journal-title":"Ann Oncol"},{"issue":"9","key":"2020071308425005000_djz215-B8","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020071308425005000_djz215-B9","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"issue":"11","key":"2020071308425005000_djz215-B10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"issue":"1","key":"2020071308425005000_djz215-B11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020071308425005000_djz215-B12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"issue":"5","key":"2020071308425005000_djz215-B13","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective treatment in women with breast carcinoma and osteolytic bone metastases","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"8","key":"2020071308425005000_djz215-B14","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"3","key":"2020071308425005000_djz215-B15","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/SPC.0b013e32835689cd","article-title":"Adjuvant bone-targeted therapy to prevent metastasis: lessons from the AZURE study","volume":"6","author":"Coleman","year":"2012","journal-title":"Curr Opin Support Palliat Care"},{"issue":"24","key":"2020071308425005000_djz215-B16","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1073\/pnas.0702254104","article-title":"Bisphosphonates target multiple sites in both cis- and trans-prenyltransferases","volume":"104","author":"Guo","year":"2007","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"2020071308425005000_djz215-B17","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1359\/jbmr.2000.15.11.2211","article-title":"Bisphosphonates induce breast cancer cell death in vitro","volume":"15","author":"Fromigue","year":"2000","journal-title":"J Bone Miner Res"},{"key":"2020071308425005000_djz215-B18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.bone.2010.07.016","article-title":"Bisphosphonates antitumor activity: an unrevealed side of a multifaceted drug class","author":"Clezardin","year":"2011","journal-title":"Bone"},{"issue":"22","key":"2020071308425005000_djz215-B19","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1200\/JCO.2003.99.132","article-title":"Bisphosphonates and oral cavity avascular bone necrosis","volume":"21","author":"Migliorati","year":"2003","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020071308425005000_djz215-B20","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1302\/2046-3758.63.BJR-2016-0125.R1","article-title":"Bisphosphonates and atypical subtrochanteric fractures of the femur","volume":"6","author":"Kharwadkar","year":"2017","journal-title":"Bone Joint Res"},{"issue":"12","key":"2020071308425005000_djz215-B21","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"issue":"7","key":"2020071308425005000_djz215-B22","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"issue":"2","key":"2020071308425005000_djz215-B23","doi-asserted-by":"crossref","first-page":"R13.","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"7","key":"2020071308425005000_djz215-B24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"28","key":"2020071308425005000_djz215-B25","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1200\/JCO.2012.47.2167","article-title":"German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer","volume":"31","author":"von Minckwitz","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"2020071308425005000_djz215-B26","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with Zoledronic Acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"2020071308425005000_djz215-B27","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomized trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"2020071308425005000_djz215-B28","first-page":"1353","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","year":"2015","journal-title":"Lancet"},{"key":"2020071308425005000_djz215-B29"},{"issue":"suppl; abstr","key":"2020071308425005000_djz215-B30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/jco.2015.33.15_suppl.503","article-title":"Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC Clinical Trials Group\/NRG Oncology Study S0307","volume":"33","author":"Gralow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9992","key":"2020071308425005000_djz215-B31","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"issue":"18","key":"2020071308425005000_djz215-B32","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020071308425005000_djz215-B33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann Oncol"},{"key":"2020071308425005000_djz215-B34","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO clinical practice guidelines","volume":"26(suppl 5)","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"issue":"8","key":"2020071308425005000_djz215-B35","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","article-title":"De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017","volume":"28","author":"Curigliano","year":"2017","journal-title":"Ann Oncol"},{"issue":"7","key":"2020071308425005000_djz215-B36","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"2020071308425005000_djz215-B37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"issue":"35","key":"2020071308425005000_djz215-B38","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.2017.75.4614","article-title":"Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","volume":"35","author":"Van Poznak","year":"2017","journal-title":"J Clin Oncol"},{"key":"2020071308425005000_djz215-B39","author":"Janni"},{"issue":"3","key":"2020071308425005000_djz215-B40","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"2020071308425005000_djz215-B41","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2018.36.15_suppl.501","article-title":"Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D-CARE study","volume":"36(suppl)","author":"Coleman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020071308425005000_djz215-B42","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S1470-2045(17)30603-4","article-title":"Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01\/04) trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djz215\/30438801\/djz215.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/7\/698\/33490536\/djz215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/112\/7\/698\/33490536\/djz215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T12:48:48Z","timestamp":1594644528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/112\/7\/698\/5613900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":42,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,11,6]]},"published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djz215","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,7]]},"published":{"date-parts":[[2019,11,6]]}}}